Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

Delayed Quote. Delayed  - 09/23 04:59:41 pm
296.8 DKK   -2.37%
09/23 NOVO NORDISK A/ : submits application in the US for including data f..
09/21 NOVO NORDISK A/ : semaglutide reduced major cardiovascular events in..
09/20 NOVO NORDISK A/ : Diabetes Campaign Launched in Nigeria to Promote E..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
09/19/2016 09/20/2016 09/21/2016 09/22/2016 09/23/2016 Date
308.8(c) 308.7(c) 307.7(c) 304(c) 296.8(c) Last
2 320 989 2 805 554 2 292 243 2 933 786 3 698 765 Volume
+0.42% -0.03% -0.32% -1.20% -2.37% Change
More quotes
Financials ( DKK)
Sales 2016 113 146 M
EBIT 2016 49 205 M
Net income 2016 38 289 M
Finance 2016 11 894 M
Yield 2016 2,44%
Sales 2017 120 056 M
EBIT 2017 52 303 M
Net income 2017 41 223 M
Finance 2017 12 025 M
Yield 2017 2,63%
P/E ratio 2016 19,58
P/E ratio 2017 17,93
EV / Sales2016 5,17x
EV / Sales2017 4,88x
Capitalization 597 329 M
More Financials
Company
Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products.It operates through the Diabetes and Obesity Care; and Biopharmaceuticals segments.The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related... 
Sector
Pharmaceuticals
Calendar
10/28Earnings Release
More about the company
Surperformance© ratings of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVO NORDISK A/S
09/23 NOVO NORDISK A/S : submits application in the US for including data from the two..
09/21 NOVO NORDISK A/S : semaglutide reduced major cardiovascular events in 1 in 4 typ..
09/20 NOVO NORDISK A/S : Diabetes Campaign Launched in Nigeria to Promote Early Diagno..
09/19 NOVO NORDISK A/S : NovoRapid receives positive CHMP opinion for extended use in ..
09/19 NOVO NORDISK A/S : - Share repurchase programme
09/16 NOVO NORDISK A/S : Victoza lowered the progression of kidney damage in adults wi..
09/16 NOVO NORDISK A/S : NovoRapid® receives positive CHMP opinion for extended use in..
09/15 NOVO NORDISK A/S : Inc. issues voluntary nationwide recall of six batches of Glu..
09/15 NOVO NORDISK A/S : Researchers from Novo Nordisk Report New Studies and Findings..
09/15 NOVO NORDISK A/S : Victoza® lowered the progression of kidney damage in adults w..
More news
Sector news : Pharmaceuticals - NEC
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/23 Endo International CEO steps down, Campanelli named successor
09/23DJSHIRE : Files 8K - Direct Or Off-Balance Sheet Financial Obligation
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/23 Novo submits application to FDA to include beefed up data in Tresiba label
09/19 Healthcare Top Dogs See Big Pharma Up 6-4 In September Gains
09/19 NASTY WEEKEND : Time To Think Through Trump-Era Investing
09/13 Google's Diabetes Partnerships Could Be Just The Start
09/13 Astra And Lexicon Provide The Good News In Diabetes
Advertisement
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 31
Average target price 363  DKK
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lars Rebien Sørensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Alan C. Moses Global Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S-25.78%90 059
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results